Elevated insulin‐like growth factor‐1 in patients without clinical evidence of acromegaly
Authors' conclusion
Out of 1963 patients having IGF-1 measured, 102 (5.2%) had an elevated IGF-1 where there was no known acromegaly, GH replacement or endogenous glucocorticoid excess. Intraindividual biological variability, assay imprecision and physiological factors are known contributors to falsely elevated IGF-1, dopamine agonist therapy and CKD should also be considered.
Study context
- Population
- Adults ≥18 years with IGF-1 measured at Pathology Queensland, 1/12/2018–1/12/2020, without clinically suspected GH excess2,759 IGF-1 samples
- Participants
- 1,963 adults
- Comparison
- Patients with elevated IGF-1 vs matched controls with normal IGF-1
- Casesn = 102
- Controlsn = 102reference
- Outcome
- Frequency of IGF-1 elevation in patients without clinically suspected GH excess
- Follow-up
- 24-month period
Methodological detailsmatched controls, single reference laboratory
- Matched controls
- Single reference laboratory
Main finding
As reported in the abstract
Elevated IGF-1 without known acromegaly, GH replacement or endogenous glucocorticoid excess
Patients with elevated IGF-1 among 1963 measured
102
5.2%
Observational data: associations, not effects.
Further findings
| Outcome | Cases | Controls | OR (95% CI) | P value | |
|---|---|---|---|---|---|
| Dopamine agonist use | 19/102 | 6/102 | 3.66 (1.45–9.29) | P = 0.009 | |
| CKD | 14/102 | 4/102 | 3.90 (1.28–11.14) | P = 0.024 | |
| 0.050.21520Odds ratio (log scale) |
Original publication
Elevated insulin‐like growth factor‐1 in patients without clinical evidence of acromegaly. Clin Endocrinol (Oxf). Published 26 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →